Dermata Therapeutics, Inc.
DRMADermata Therapeutics is a science-driven skincare company focused on developing and commercializing products for common and underserved skin conditions.
Table of contents
Earnings
Next report
Aug 18, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Dermata Therapeutics is a science-driven skincare company focused on developing and commercializing products for common and underserved skin conditions. The company leverages its proprietary Bioneedle technology, derived from the freshwater sponge Spongilla lacustris, to create both cosmetic and over-the-counter (OTC) treatments. Its core value proposition lies in bridging the gap between traditional natural remedies and clinical rigor to provide effective, non-prescription skintech solutions.
Dermata is strategically repositioning from a prescription-focused biotech to a consumer-facing skincare brand, utilizing a unique, patented biological hero ingredient to differentiate itself in the crowded OTC and cosmetic markets.
Questions, answered.
- What is Dermata Therapeutics, Inc.'s market cap?
- Dermata Therapeutics, Inc. (DRMA) has a market capitalization of $5.4M and trades on NASDAQ.
- Who are Dermata Therapeutics, Inc.'s competitors?
- Dermata Therapeutics, Inc.'s key competitors include Hims & Hers Health, Inc., Neutrogena, La Roche-Posay, and others. These companies compete in similar markets and product categories.
- Who does Dermata Therapeutics, Inc. partner with?
- Dermata Therapeutics, Inc.'s notable partners include Revance Therapeutics, Inc., Reka-Farm LLC.
- Where is Dermata Therapeutics, Inc. headquartered?
- Dermata Therapeutics, Inc. is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 2021.